Reference Library | ProtoCall LLC

FDA — Pharmaceuticals and Biologics

Principal U.S. drug GMP and validation references

Reference	Type	Primary Scope	Plain Description
Federal Food, Drug, and Cosmetic Act	Statute	CGMP, drug manufacturing, finished pharmaceuticals, biological products, approval to market for new drugs, medical devices, and quality system	The foundational U.S. law under which FDA regulates drugs, biological products, and medical devices. It provides statutory authority for CGMP, drug approval, medical device oversight, and related quality-system expectations.
21 CFR Part 210	Regulation	General CGMP requirements for drugs	Establishes the baseline U.S. CGMP framework for drug manufacturing and is read together with Part 211.
21 CFR Part 211	Regulation	Finished pharmaceutical CGMP requirements	Covers facilities, equipment, components, production controls, laboratory controls, records, and packaging or labeling for finished drugs.
21 CFR Part 11	Regulation	Electronic records and electronic signatures	Defines when electronic records and signatures are considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.
21 CFR Part 212	Regulation	PET drug CGMP requirements	Applies CGMP requirements specific to positron emission tomography drug production.
21 CFR Parts 600–680	Regulation	Biological products	Provides biologics-related regulatory requirements that may apply alongside general drug CGMP expectations.
Process Validation: General Principles and Practices	Guidance	Lifecycle process validation	FDA’s principal process-validation guidance; explains process design, process qualification, and continued process verification.
Data Integrity and Compliance With Drug CGMP: Questions and Answers	Guidance	Drug data integrity	Clarifies FDA expectations for completeness, consistency, accuracy, review, and control of CGMP data.
Questions and Answers on Current Good Manufacturing Practice Regulations for Production and Process Controls	Guidance / Q&A	Production and process control interpretation	Provides FDA interpretation on production and process-control expectations relevant to validation and manufacturing oversight.

FDA — Medical Devices

Principal device quality-system and software-validation references

Reference	Type	Primary Scope	Plain Description
21 CFR Part 820 (QMSR)	Regulation	Medical device quality system requirements	FDA’s device quality management regulation, now titled the Quality Management System Regulation and aligned more closely with ISO 13485.
21 CFR Part 803	Regulation	Medical device reporting	Defines reporting obligations for certain adverse events and device-related incidents.
21 CFR Part 806	Regulation	Corrections and removals	Sets requirements for reporting and documenting certain field corrections or product removals.
21 CFR Part 807	Regulation	Registration, listing, and premarket notification	Applies to establishment registration, device listing, and many 510(k)-related activities.
General Principles of Software Validation	Guidance	Medical device software and software used in device production	FDA’s principal software-validation guidance for medical device software and software used to design, develop, or manufacture devices.
QMSR resources	Guidance / resource set	Transition to revised Part 820	Provides implementation context for the revised device quality-system regulation and its alignment approach.

AI System Validation

Targeted references for AI-enabled systems used in pharmaceutical and biologics environments

Reference	Type	Primary Scope	Plain Description
FDA — Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products	Guidance	AI credibility in drug and biologics submissions	FDA’s principal current guidance for AI used to generate information supporting regulatory decisions for drug and biological products. It introduces a risk-based credibility assessment framework centered on the model’s context of use.
FDA — Artificial Intelligence for Drug Development	Program / resource page	AI across the drug product lifecycle	Summarizes FDA’s current drug-development focus areas for AI and confirms that AI is being used across nonclinical, clinical, postmarketing, and manufacturing phases of the drug lifecycle.
FDA — Guiding Principles of Good AI Practice in Drug Development	Agency principles	Good AI practice for drug development	Sets out FDA’s current good-AI-practice principles for drug development, emphasizing reliability, governance, context of use, data quality, monitoring, and lifecycle control.
21 CFR Part 11	Regulation	Electronic records and electronic signatures	Remains directly relevant when an AI-enabled system creates, stores, reviews, or supports regulated electronic records or approvals in a GMP environment.
21 CFR Parts 210 and 211	Regulation	Drug CGMP requirements	These core CGMP regulations still govern AI-enabled systems used in pharmaceutical manufacturing, laboratories, quality oversight, or production support. AI does not replace the need for validated process and system controls.
EU GMP Annex 11	Annex guidance	Computerised systems	Continues to be one of the most important references for AI-enabled GMP computerized systems because lifecycle validation, security, backup, audit trails, and procedural control still apply even when AI is involved.
EU GMP Annex 15	Annex guidance	Qualification and validation	Provides the broader qualification and validation framework that still governs the validation strategy for AI-enabled systems used in GMP operations.
ISPE GAMP® AI guidance family	Industry guidance	AI-enabled GxP computerized systems	ISPE states that its GAMP AI guidance provides a pragmatic framework for AI-enabled computerized systems that are fit for intended use and aligned with current regulatory expectations.
ISPE article — New EU AI Regulation and GAMP® 5	Article / commentary	Application of GAMP to AI systems	Explains how GAMP 5 and related guidance can be applied to qualification and compliance management for AI and machine learning systems in regulated environments.
ISPE article — Validating Artificial Intelligence with Probabilistic Output in Good Practice	Article / commentary	Validation challenges for AI outputs	Addresses one of the most important QA issues in AI system validation: how to justify intended use, test strategy, acceptance criteria, and control of probabilistic or non-deterministic outputs.
PDA data integrity technical report family	Technical report family	Data integrity controls in computerized environments	Although not AI-specific, PDA’s data integrity framework remains highly relevant to AI-enabled systems because record reliability, governance, review, and procedural control remain mandatory quality expectations.

Health Canada

Canadian law, GMP regulations, and validation-relevant guidance

Reference	Type	Primary Scope	Plain Description
Food and Drugs Act	Statute	Canadian statutory framework	The main Canadian law governing food, drugs, cosmetics, and therapeutic products.
Food and Drug Regulations	Regulation	Detailed drug regulatory requirements	Contains operational regulatory requirements, including GMP-related provisions applicable to drug establishments and products.
GUI-0001: Good Manufacturing Practices Guide for Drug Products	Guidance	Interpretation of Canadian GMP requirements	Health Canada’s main interpretation guide for GMP requirements in Part C, Division 2 of the Food and Drug Regulations.
GUI-0069: Guidelines for Environmental Control During Storage and Transportation of Drugs	Guidance	Storage, temperature, and transport controls	Explains how firms should control environmental conditions for drug storage and transport, including temperature-related requirements.
Health Canada GMP guidance library	Guidance library	Topic-specific GMP interpretation	Includes additional documents relevant to GMP interpretation, inspections, computerized systems, sterile drugs, and specific regulated activities.

European Union

EudraLex Volume 4 and principal annexes used in validation work

Reference	Type	Primary Scope	Plain Description
EudraLex Volume 4	EU GMP framework	GMP interpretation for medicinal products	The core EU GMP framework for medicinal products, including chapters and annexes used to structure qualification, validation, sterile manufacturing, and computerized system compliance.
Annex 1	Annex guidance	Sterile medicinal products	Defines EU expectations for manufacture of sterile medicinal products, contamination control, cleanroom strategy, and aseptic process oversight.
Annex 11	Annex guidance	Computerised systems	Provides EU GMP expectations for computerized systems, including lifecycle control, security, backup, audit trails, and validation.
Annex 15	Annex guidance	Qualification and validation	Defines the EU framework for qualification and validation of facilities, utilities, equipment, processes, cleaning, and related lifecycle controls.
Other annexes in Volume 4	Annex set	Topic-specific GMP interpretation	Other annexes may apply depending on the product type, dosage form, system, or manufacturing activity under review.

MHRA

UK guidance commonly used in validation and data-integrity assessments

Reference	Type	Primary Scope	Plain Description
Guidance on GxP Data Integrity	Guidance	Data integrity across regulated activities	MHRA’s principal guidance on data-integrity expectations used in pharmaceutical lifecycle and GLP-regulated environments.
Good manufacturing practice and good distribution practice	Regulatory guidance page	Inspection and licensing expectations	Explains MHRA’s GMP and GDP inspection framework and how licensed sites are assessed for compliance.
Related MHRA GMP/GDP publications	Guidance library	Topic-specific UK compliance expectations	Additional MHRA publications may apply depending on licensing status, import or distribution model, and the systems under review.

Industry Standards and Technical Organizations

ASTM, ISPE, and PDA references commonly used in validation practice

In addition to agency regulations and guidance, validation programs often rely on widely adopted standards, good practice guides, technical reports, and industry publications. The references below highlight commonly used ASTM, ISPE, and PDA resources that frequently support qualification, computerized systems, process validation, data integrity, facilities, and utility work.

ASTM International

Popular ASTM standards and reference materials

Reference	Type	Primary Scope	Plain Description
ASTM E2500	Standard Guide	Specification, design, and verification of manufacturing systems	A widely used risk- and science-based framework for qualification and verification of pharmaceutical and biopharmaceutical manufacturing systems and equipment.
ASTM E2537	Standard Guide	Continuous process verification	Provides a framework for applying continuous process verification concepts as part of an ongoing process-validation strategy.
ASTM E2898	Standard Guide	Risk-based validation of analytical methods for PAT applications	Extends E2500 principles into process analytical technology and analytical-method lifecycle validation for PAT use cases.
ASTM Committee E55 publications and roadmaps	Committee resource	Pharmaceutical and biopharmaceutical manufacturing standards	Committee E55 materials help identify the major ASTM standards commonly used in pharmaceutical manufacturing, qualification, PAT, and related lifecycle activities.
ASTM pharmaceutical manufacturing articles	Article / overview	Standards awareness and industry application	ASTM overview articles highlight the standards most frequently referenced in pharmaceutical manufacturing and explain where they are commonly applied in practice.

ISPE

Reference	Type	Primary Scope	Plain Description
ISPE Baseline Guide Volume 5: Commissioning and Qualification (2nd Edition)	Baseline Guide	Science- and risk-based C&Q	One of the most frequently used ISPE references for modern commissioning and qualification strategy, including system risk assessment and critical aspect identification.
ISPE Good Practice Guide: Approaches to Commissioning and Qualification of Pharmaceutical Water and Steam Systems	Good Practice Guide	Critical utilities	Provides practical approaches to commissioning and qualifying pharmaceutical water and steam systems used in GMP environments.
GAMP guidance family	Good Practice Guide family	Computerized systems and automation	ISPE’s GAMP guidance remains a leading industry framework for lifecycle management, validation, and governance of GxP computerized systems.
ISPE HVAC and critical utility guidance	Good Practice Guide family	Facilities and utilities	These guides support qualification strategy, design review, and lifecycle control for key facility systems used in regulated manufacturing operations.
ISPE Baseline® Guide: Volume 3 — Sterile Manufacturing Facilities	Baseline Guide	Sterile manufacturing facilities and microbiological control interface	Microbiology-relevant ISPE baseline reference for sterile facility design and operation. Useful when evaluating cleanroom design, aseptic processing support areas, facility flows, contamination-control expectations, and the engineering controls that support microbiological quality.
ISPE topic pages and commentary on C&Q / GAMP	Article / commentary	Implementation interpretation	ISPE articles and topic pages provide implementation context, lessons learned, and practical interpretation for applying baseline guides and GAMP guidance.

Popular PDA technical reports, articles, and white-paper style resources

Reference	Type	Primary Scope	Plain Description
PDA Technical Report No. 13: Fundamentals of an Environmental Monitoring Program	Technical Report	Environmental monitoring and microbiological control	A key microbiology reference for environmental monitoring program design and interpretation. Relevant to viable air, surface, personnel monitoring, alert/action levels, contamination investigations, and microbiological trend evaluation in controlled environments.
PDA Technical Report No. 80: Data Integrity Management System for Pharmaceutical Laboratories	Technical Report	Laboratory data integrity framework	A widely referenced PDA report that outlines risks, controls, and management-system concepts for building a robust laboratory data integrity program.
PDA data integrity technical report series	Technical Report series	Data integrity within the quality management system	PDA describes this report series as a roadmap for integrating a data integrity management system into the broader quality management system.
PDA catalog of technical documents	Catalog / reference list	Technical report inventory	The PDA catalog is useful for identifying commonly cited reports related to data integrity, quality culture, process validation, microbiology, and pharmaceutical manufacturing practice.
PDA articles on data integrity and quality systems	Article / white-paper style resource	Program design and practical implementation	PDA publishes practical articles that help translate data integrity and quality-system expectations into operational controls and management actions.
PDA digital transformation and pharmaceutical technology publications	Publication family	Automation, modernization, and compliance	These PDA publications provide industry-facing interpretation on emerging technologies and how they intersect with regulated manufacturing and compliance expectations.

Targeted Topic References

Autoclaves, CTUs, and cold storage references frequently used in QA and validation work

The references below are grouped by validation topic. Some entries intentionally duplicate broader regulatory sources already listed elsewhere in this library because they are especially relevant to autoclave qualification, moist heat sterilization, controlled temperature units, cold rooms, refrigerators, freezers, and insulated shipping systems or cold boxes.

Autoclaves and Moist Heat Sterilization

Targeted references for steam sterilization, sterilizer qualification, and sterility assurance

Reference	Type	Primary Scope	Plain Description
FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice	Guidance	Steam sterilization and aseptic processing controls	Includes FDA’s core expectations for autoclave cycle validation, air removal, load pattern definition, biological indicators, temperature sensors, and documented cycle records for sterile drug operations.
FDA Sterilization Process Controls	Inspection guide	Validated sterilization process control	Explains FDA inspection focus areas for sterilization process controls and reinforces that validated, monitored, and controlled sterilization processes are essential to assure product conformance.
EU GMP Annex 1 — Moist Heat Sterilization	Annex guidance	Sterile medicinal products	Provides EU expectations for moist heat sterilization, including validated cycle design, monitoring, routine control, and lifecycle oversight of steam or superheated-water sterilization processes.
FDA Sterilization for Medical Devices	Regulatory overview	Device sterilization methods	Summarizes sterilization methods used for medical devices and is useful when moist heat sterilization is part of a device or reusable-device program.
FDA Recognized Consensus Standard — AAMI ST79	Recognized consensus standard	Steam sterilization and sterility assurance	FDA recognition of AAMI ST79 makes it a relevant supporting consensus standard when steam sterilization practices and sterility assurance are being evaluated in applicable healthcare or device contexts.
PDA / technical sterilization resources	Technical publication family	Sterility assurance and GMP implementation	PDA publications are often used as supplemental industry references when interpreting sterilization, aseptic processing, and contamination-control practice.

CTUs, Cold Storage, and Cold Boxes

Targeted references for controlled temperature units, cold rooms, refrigerators, freezers, and insulated transport systems

Reference	Type	Primary Scope	Plain Description
Health Canada GUI-0069	Guidance	Environmental control during storage and transportation of drugs	One of the most directly relevant Canadian references for CTUs, warehouses, refrigerators, freezers, transport containers, and temperature-excursion control during storage and shipping.
MHRA Temperature Mapping — An Introduction	Article / inspectorate guidance	Temperature mapping of storage areas	Provides practical MHRA-aligned interpretation for initial temperature mapping of storage areas before use and under representative conditions, which is directly relevant to CTU qualification.
MHRA Refrigerated Medicinal Products, Part 1: Receipt and Storage	Article / inspectorate guidance	Cold storage handling	Addresses receipt and storage practices for refrigerated medicinal products and is useful for cold rooms, refrigerators, and short-term storage controls.
MHRA Refrigerated Medicinal Products, Part 2: Transportation, Packing, Temperature Management, Third-Party Couriers, and Returns	Article / inspectorate guidance	Cold-chain transportation and shipping systems	Provides practical direction for packing and transportation of refrigerated medicinal products, including the expectation that required temperatures are maintained throughout the journey.
EU GDP Guidelines Chapter 3.2.1 and Chapter 9.3	GDP guidance	Storage mapping and transport temperature control	These GDP chapters are the core EU references commonly cited for initial temperature mapping of storage areas and for temperature control during transportation of medicinal products.
Health Canada summary for storage and transportation environmental control	Guidance summary	Drug storage, handling, and transport conditions	Reinforces that drugs must be stored and transported according to labelled storage conditions or transport conditions supported by data, which is central to CTU and cold-chain qualification strategy.

USP — United States Pharmacopeia

USP chapters and resources commonly used in validation, laboratory qualification, sterile manufacturing, utilities, and cold-chain control

USP chapters are frequently used as compendial and informational references during pharmaceutical quality, validation, laboratory, utility, microbiology, sterile manufacturing, and storage/distribution work. Some entries below duplicate other topic sections because they are highly relevant to QA review and validation strategy.

Reference	Type	Primary Scope	Plain Description
USP–NF	Compendial standards platform	USP and National Formulary standards	The primary USP compendial platform for official monographs, general chapters, and related documentary standards. Use this as the governing source for current official text and status.
USP <71> Sterility Tests	General chapter	Sterility testing	Core sterility-test chapter for sterile products and applicable sterile medical device contexts. Important for QA review of sterility testing, method controls, aseptic test conditions, and release testing strategy.
USP <85> Bacterial Endotoxins Test	General chapter	Endotoxin testing	Defines the compendial bacterial endotoxins test framework. Relevant to injectable products, sterile products, certain devices, water systems, components, and QC laboratory method control.
USP <659> Packaging and Storage Requirements	General chapter	Storage conditions and packaging definitions	Provides packaging definitions and storage condition terminology relevant to labeled storage, cold storage, frozen storage, controlled room temperature, distribution controls, and CTU qualification strategy.
USP <1058> Analytical Instrument Qualification	General chapter	Analytical instrument and system qualification	Widely used for analytical instrument qualification and fitness-for-intended-use justification. Relevant to lab equipment URS, risk classification, IQ/OQ/PQ strategy, periodic review, and data reliability.
USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments	General information chapter	Environmental monitoring and aseptic processing control	Supports microbiological-control strategy for aseptic processing environments. Relevant to EM program design, cleanroom monitoring, contamination control, and QA interpretation of microbiological trends.
USP <1220> Analytical Procedure Life Cycle	General chapter / lifecycle framework	Analytical procedure lifecycle	Applies lifecycle thinking to analytical procedure development, validation, transfer, and ongoing performance. Relevant to method lifecycle governance, analytical target profiles, and continued procedure performance verification.
USP <1223> Validation of Alternative Microbiological Methods	General chapter	Alternative microbiological methods	Provides guidance for selecting, evaluating, and validating microbiological methods used as alternatives to compendial methods. Important for rapid microbiological methods and method-equivalency assessments.
USP <1225> Validation of Compendial Procedures	General chapter	Analytical method validation	Provides validation expectations for compendial analytical procedures. Relevant to method validation, specificity, accuracy, precision, linearity, range, detection limit, quantitation limit, robustness, and suitability for intended use.
USP <1207> Package Integrity Evaluation—Sterile Products	General chapter family	Container closure integrity and sterile package assurance	Provides guidance for evaluating the integrity of nonporous packages intended for sterile pharmaceutical products. Relevant to container closure integrity testing, sterile barrier assurance, and package lifecycle control.
USP <1229> Sterilization of Compendial Articles	General chapter family	Sterilization principles and sterilization modes	Provides an overview of sterilization concepts and supporting chapters for specific sterilization modes, including steam, moist heat, dry heat, sterilizing filtration, radiation, vapor phase, and biological indicators.
USP <1231> Water for Pharmaceutical Purposes	General information chapter / USP resource	Pharmaceutical water systems	Supports QA review of pharmaceutical water design, operation, sampling, chemical and microbiological monitoring, alert/action levels, and validation of water purification, storage, and distribution systems.
USP harmonization resources — Bacterial Endotoxins	Harmonization resource	Pharmacopeial harmonization	Useful when comparing USP expectations to harmonized pharmacopeial texts for endotoxin testing and globally aligned compendial requirements.

Sampling Plan and Statistical Analysis

Regulatory, compendial, technical, and software references for sampling plans and statistical justification

Sampling plans and statistical methods must be justified by intended use, process risk, product risk, data type, lifecycle stage, and the decision being made. In GMP work, a sampling plan should identify the population or lot, sampling locations, sample size, acceptance criteria, statistical rationale, confidence or coverage basis where applicable, and the method used to evaluate results.

Reference	Type	Primary Scope	Plain Description
FDA Process Validation: General Principles and Practices	FDA guidance	Process validation lifecycle and continued process verification	Core FDA process validation guidance. Relevant to statistically justified PPQ sampling, continued monitoring, process variability estimates, capability evaluation, and lifecycle control strategy.
ICH Q9(R1) Quality Risk Management / FDA adoption	FDA / ICH guidance	Quality risk management and risk-based decision-making	Provides the risk-management framework used to justify sampling intensity, formality of statistical treatment, monitoring frequency, and escalation thresholds based on patient and product risk.
ICH Q2(R2) Validation of Analytical Procedures / FDA adoption	FDA / ICH guidance	Analytical procedure validation	Provides the general framework for validating analytical procedures, including accuracy, precision, specificity, detection and quantitation limits, range, and robustness.
ICH Q14 Analytical Procedure Development / FDA adoption	FDA / ICH guidance	Analytical procedure development and lifecycle	Supports science- and risk-based analytical development, including enhanced approaches that inform validation design and statistical evidence expectations.
EU GMP Annex 15: Qualification and Validation	EU GMP annex	Qualification and validation planning	Requires validation and qualification work to be planned across the lifecycle. Relevant to predefined sampling plans, acceptance criteria, validation protocols, and documented rationale for the extent of qualification or validation.
EMA / ICH Q9(R1) Quality Risk Management	EU / ICH guidance	Quality risk management	Provides EU-recognized principles for risk-based sampling, monitoring, and statistical analysis decisions across pharmaceutical development, manufacturing, distribution, and inspections.
MHRA GxP Data Integrity Guidance	MHRA guidance	Data reliability and statistical processing control	Relevant when statistical analysis, averaging, data exclusion, audit trail review, electronic records, or calculated results are used to support GxP decisions.
MHRA Temperature Mapping — An Introduction	MHRA inspectorate article	Temperature mapping and storage qualification	Useful for CTU and warehouse sampling designs because probe placement, mapping duration, seasonal conditions, and representative operating conditions must be justified.
Health Canada GUI-0119: Manufacture of Sterile Drugs — Quality Control	Health Canada guidance	Sterile drug quality control and representative sampling	States that finished-product sterility testing is only one control in a broader sterility assurance strategy and that samples should be representative of the batch and areas at highest contamination risk.
Health Canada GUI-0069: Environmental Control During Storage and Transportation	Health Canada guidance	Storage, transport, CTU, and warehouse controls	Relevant to CTU and cold-chain mapping plans, storage condition justification, excursion assessment, and monitoring strategy for warehouses, refrigerators, freezers, and transport systems.
USP <1058> Analytical Instrument Qualification	USP general chapter	Analytical instrument qualification	Relevant to statistical software and laboratory systems used to generate, process, or evaluate analytical data. Supports fitness-for-intended-use and qualification strategy for instruments and systems.
USP <1210> Statistical Tools for Procedure Validation	USP general chapter / training resource	Statistical tools for analytical procedure validation	Provides statistical concepts used in procedure validation and complements USP <1225>. Relevant to accuracy, precision, LOD, LOQ, and validation study design.
USP <1225> Validation of Compendial Procedures	USP general chapter	Analytical method validation	Relevant to statistical evaluation of method validation parameters, including precision, accuracy, linearity, range, robustness, and method suitability.
USP <1223> Validation of Alternative Microbiological Methods	USP general chapter	Alternative and rapid microbiological methods	Provides a framework for validating microbiological alternatives to compendial methods, including comparison to existing methods and evaluation of performance characteristics.
ASTM E2709	ASTM standard practice	Acceptance procedure capability	Useful for demonstrating capability to comply with a lot acceptance procedure using statistically defined acceptance criteria based on individual results or sample statistics.
ASTM E2281	ASTM standard practice	Process and measurement capability indices	Used to support process capability and performance measurement, including Cpk, Ppk, and other capability metrics when the process is statistically controlled and assumptions are appropriate.
ASTM E2587	ASTM standard practice	Control charts in statistical process control	Useful for continued process verification, trend monitoring, process stability assessment, and detecting special-cause variation during routine production.
ISPE Blend Uniformity and Content Uniformity Tools	ISPE tools / technical resource	Blend and dosage-unit uniformity assessment	Provides tools associated with ASTM E2709/E2810 methodology for final dosage-unit evaluation and acceptance-limit calculation.
ISPE Role of Process Capability in Monitoring Product Quality	ISPE white paper	Process capability and control strategy	Discusses process capability and how capability indices can support product and process understanding, control strategy, and ongoing monitoring.
PDA Technical Report No. 59: Utilization of Statistical Methods for Production Monitoring	PDA technical report	Statistical process control in pharmaceutical production	Presents practical statistical process control methods applicable to pharmaceutical production monitoring and continued process verification.
PDA Technical Report No. 57: Analytical Method Validation and Transfer for Biotechnology Products	PDA technical report	Risk-based analytical method validation and transfer	Provides practical and strategic guidance for using historical data and knowledge to design suitable risk-based analytical method validation studies.
PDA Technical Report No. 57-2: Analytical Method Development and Qualification for Biotechnology Products	PDA technical report	Analytical method development and qualification	Provides risk-based guidance for method development and qualification portions of the analytical method lifecycle for biotechnology products.
Minitab Statistical Software	Statistical software package	Commonly validated statistical analysis platform	Often used for capability analysis, control charts, DOE, hypothesis testing, regression, and validation statistics. Minitab provides a software validation kit to support customer validation for intended use.
JMP Statistical Discovery Software	Statistical software package	Commonly qualified statistical analysis tool	Used for DOE, visualization, regression, capability analysis, and process understanding. In FDA-regulated use, the implemented system and intended workflows still require customer qualification or validation.
SAS	Statistical software package	Clinical, regulatory, and life-science statistical analysis	Widely used in life sciences and clinical/regulatory analysis environments. Validation remains the user organization’s responsibility based on intended use, governed workflows, records, and procedures.
Statgraphics	Statistical software package	Statistical analysis with 21 CFR Part 11 support features	Provides statistical tools and Part 11-oriented features such as audit trail, passwords, and signatures. The vendor notes that compliant use still depends on proper configuration and procedural controls.
R / R-based statistical computing environment	Statistical software environment	Open-source statistical computing	Can be used in regulated work when the environment, packages, scripts, version control, data handling, testing, and output review are controlled and validated for intended use. R itself is not FDA-validated out of the box.

Reference Notes

Important use limitations

A complete list of every current agency guidance document is too large and too changeable to maintain accurately on a standard marketing website page. This library is therefore structured as a curated reference index built around the principal regulations, the most validation-relevant guidance families, and the most commonly cited industry standards.

Reference Library for Validation and Regulatory Compliance.

How to use this page